title: A victory for global public health in the Indian Supreme Court.
abstract: On 1 April of this year, the Indian Supreme Court upheld the decision of the Indian Patent Office to refuse the patent grant for Novartis imatinib mesylate (Gleevec). The patent application failed to meet the requirements for patentability under Indian law. The global public health community followed the case closely. Its outcome could affect the Indian generics industry - an important supplier of low cost medicines to the developing world.
authors.forename: Ellen
authors.initials: E
authors.lastname: 't Hoen
mesh_terms: D000970:Antineoplastic Agents; D001549:Benzamides; D016527:Drug Costs; D016568:Drugs, Generic; D000068877:Imatinib Mesylate; D007194:India; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D010879:Piperazines; D011634:Public Health; D011743:Pyrimidines
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016568:Drugs, Generic; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate